[go: up one dir, main page]

MA27317A1 - Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie - Google Patents

Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie

Info

Publication number
MA27317A1
MA27317A1 MA28033A MA28033A MA27317A1 MA 27317 A1 MA27317 A1 MA 27317A1 MA 28033 A MA28033 A MA 28033A MA 28033 A MA28033 A MA 28033A MA 27317 A1 MA27317 A1 MA 27317A1
Authority
MA
Morocco
Prior art keywords
diabetes
dyslipidemia
obesity
beta
treatment
Prior art date
Application number
MA28033A
Other languages
English (en)
Inventor
Steven H Olson
James M Balkovec
Yuping Zhu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA27317A1 publication Critical patent/MA27317A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INHIBITEURS DE LA 11-BETA-HYDROXYSTEROiDE DEHYDROGENASE 1 UTILES POUR LE TRAITEMENT DU DIABETE, DE L'OBESITE ET DE LA DYSLIPIDEMIE Les composés ayant la Formule I, comprenant les sels pharmaceutiquement acceptables, hydrates et solvates de ceux-là : sont des inhibiteurs sélectifs de l'enzyme 11(beta)-HSD1. Les composés sont utiles pour le traitement du diabète, tel que le diabète non insulinodèpendant (DNID), l'hyperglycémie, l'obésité, la résistance à l'insuline, la dyslipidémie, l'hyperlipidémie, l'hypertension, le Syndrome X, et les autres symptômes liés au DNID.
MA28033A 2002-06-10 2005-01-05 Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie MA27317A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38738502P 2002-06-10 2002-06-10

Publications (1)

Publication Number Publication Date
MA27317A1 true MA27317A1 (fr) 2005-05-02

Family

ID=29736306

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28033A MA27317A1 (fr) 2002-06-10 2005-01-05 Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie

Country Status (28)

Country Link
US (2) US6730690B2 (fr)
EP (1) EP1532122B1 (fr)
JP (1) JP4405384B2 (fr)
KR (1) KR20050008805A (fr)
CN (2) CN1990474A (fr)
AR (1) AR040241A1 (fr)
AT (1) ATE537155T1 (fr)
AU (2) AU2003243420A1 (fr)
BR (1) BR0311137A (fr)
CA (1) CA2488592C (fr)
EC (1) ECSP045482A (fr)
ES (1) ES2377200T3 (fr)
HR (1) HRP20041180A2 (fr)
IL (1) IL165257A0 (fr)
IS (1) IS7519A (fr)
JO (1) JO2315B1 (fr)
MA (1) MA27317A1 (fr)
MX (1) MXPA04012381A (fr)
MY (1) MY134664A (fr)
NO (1) NO20050102L (fr)
NZ (1) NZ536188A (fr)
PE (1) PE20040726A1 (fr)
PL (1) PL373372A1 (fr)
RU (1) RU2319703C2 (fr)
TW (1) TWI324153B (fr)
UA (1) UA81417C2 (fr)
WO (2) WO2003104207A2 (fr)
ZA (1) ZA200408772B (fr)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
WO2003059267A2 (fr) * 2001-12-21 2003-07-24 Rhode Island Hospital INHIBITEURS SELECTIFS DE 11β-HSD ET LEURS PROCEDES D'UTILISATION
CA2474168A1 (fr) 2002-02-01 2003-08-14 Merck & Co., Inc. Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
WO2004097002A2 (fr) * 2003-04-29 2004-11-11 The Miriam Hospital Inhibiteurs 11?-hsd de testosterone selectifs et methodes d'utilisation
WO2004103993A1 (fr) 2003-05-14 2004-12-02 Syrrx, Inc. Inhibiteurs de dipeptidyl peptidase
US20070099884A1 (en) * 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
BRPI0413452A (pt) 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
PL1663185T3 (pl) 2003-09-22 2009-06-30 Onepharm Res & Development Gmbh Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego
WO2005044192A2 (fr) 2003-10-28 2005-05-19 Amgen Inc. Composes triazole et utilisations associees
US20050137209A1 (en) * 2003-12-18 2005-06-23 Agy Therapeutics, Inc. Treatment of neurologic disorders with inhibitors of 11beta-HSD1
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
JP2007519726A (ja) * 2004-01-26 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の、新規結晶形態
US7354938B2 (en) 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto
AU2005230864A1 (en) 2004-03-29 2005-10-20 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US20050261302A1 (en) * 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
EA011097B1 (ru) 2004-05-07 2008-12-30 Янссен Фармацевтика Н.В. Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
EA011021B1 (ru) 2004-05-07 2008-12-30 Янссен Фармацевтика Н.В. Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2005121132A1 (fr) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. Composé hétérocyclique fondu ayant un effet anti-vhc
US20060025445A1 (en) * 2004-08-02 2006-02-02 Xiang Jason S 11-Beta HSD1 inhibitors
GB0418877D0 (en) * 2004-08-24 2004-09-29 Univ Edinburgh Heart
AU2005279209B2 (en) 2004-08-30 2011-03-24 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-BETA hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
ES2338441T3 (es) 2004-08-30 2010-05-07 Janssen Pharmaceutica Nv Derivados de n-2-adamantil-2-fenoxi-acetamida como inhibidores de 11-betahidroxiesteroide-deshidrogenasa.
WO2006030805A1 (fr) * 2004-09-16 2006-03-23 Astellas Pharma Inc. Dérivé de triazole ou sel dudit dérivé
WO2006105127A2 (fr) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Inhibiteurs de l'hydroxysteroide deshydrogenase
WO2006106052A1 (fr) 2005-04-05 2006-10-12 F. Hoffmann-La Roche Ag 1h-pyrazole 4-carboxylamides, preparation et utilisation de ceux-ci comme 11-beta-hydroxysteroide deshydrogenase
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1894919B1 (fr) * 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Composé hétérocyclique ayant une activité d'inhibition de la 11 -beta-hydroxystéroïde déshydrogenase de type i
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CA2622642C (fr) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidylpeptidase
RU2302066C1 (ru) * 2005-09-22 2007-06-27 Научный центр волоконной оптики при Институте общей физики им. А.М. Прохорова Российской академии наук Волоконный световод для оптического усиления излучения на длине волны в диапазоне 1000-1700 нм, способы его изготовления и волоконный лазер
WO2007041052A2 (fr) 2005-09-29 2007-04-12 Merck & Co., Inc. Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4
RU2443689C2 (ru) 2005-11-21 2012-02-27 Сионоги Энд Ко., Лтд. ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА
WO2007084314A2 (fr) * 2006-01-12 2007-07-26 Incyte Corporation MODULATEURS de la 11-ß HYDROXYSTEROIDE DESHYDROGENASE DE TYPE 1, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCEDES D'UTILISATION
BRPI0710479A2 (pt) 2006-01-18 2012-08-14 Hoffmann La Roche composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica.
WO2007088895A1 (fr) * 2006-01-31 2007-08-09 Mochida Pharmaceutical Co., Ltd. Derive de 3-arylamino-1,2,4-triazole
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
BRPI0708782A2 (pt) 2006-03-16 2011-06-14 Astellas Pharma Inc derivado de triazol ou um sal deste
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
CN107007581A (zh) 2006-08-24 2017-08-04 田纳西大学研究基金会 取代的n‑酰基苯胺及其使用方法
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008039327A2 (fr) 2006-09-22 2008-04-03 Merck & Co., Inc. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
ES2535317T3 (es) 2007-05-18 2015-05-08 Shionogi & Co., Ltd. Derivado heterocíclico que contiene nitrógeno que tiene actividad inhibidora de la 11 beta-hidroxiesteroide deshidrogenasa de tipo 1
WO2009001817A1 (fr) 2007-06-27 2008-12-31 Taisho Pharmaceutical Co., Ltd. COMPOSÉ AYANT UNE ACTIVITÉ D'INHIBITION DE LA 11β-HSD1
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8394823B2 (en) * 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
WO2009126624A1 (fr) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Composés triazolos utiles en tant qu'inhibiteurs de dgat1
SMT201700154T1 (it) * 2008-07-03 2017-05-08 Astellas Pharma Inc Derivato di triazolo o suo sale
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
CA2741644C (fr) 2008-10-30 2013-05-07 Merck Sharp & Dohme Corp. Antagonistes d'isonicotinamide des recepteurs de l'orexine
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
CN102395567A (zh) * 2009-02-12 2012-03-28 埃克塞利希斯股份有限公司 在治疗糖尿病和肥胖症中用作的tgr5激动剂的三唑和咪唑衍生物
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
CA2768577A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase
US8552022B2 (en) 2009-08-13 2013-10-08 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2011023754A1 (fr) 2009-08-26 2011-03-03 Sanofi-Aventis Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation
US8455533B2 (en) 2009-09-02 2013-06-04 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
AR077851A1 (es) * 2009-12-11 2011-09-28 Exelixis Inc Agonistas del tgr5
WO2011103256A1 (fr) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Aminotétrahydrothiopyranes substitués et dérivés de ceux-ci utilisés en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le cadre du traitement du diabète
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2571876B1 (fr) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2605658B1 (fr) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Composés spiroxazolidinone
UA112418C2 (uk) 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012138845A1 (fr) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Composés à cyclopropyle substitué, compositions contenant de tels composés et méthodes de traitement
EP2700643B1 (fr) 2011-04-19 2016-11-23 Daiichi Sankyo Company, Limited Dérivé de tétrahydrothiazépine
CN103687855A (zh) 2011-06-02 2014-03-26 英特维特国际股份有限公司 咪唑衍生物
US9006228B2 (en) 2011-06-16 2015-04-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2760855B1 (fr) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Composés de cyclopropyle substitués, compositions contenant ces composés ainsi que leur utilisation pour le traitement du diabète de type 2
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
WO2013068328A1 (fr) 2011-11-07 2013-05-16 Intervet International B.V. Composés d'acide bicyclo[2.2.2]octan-1-ylcarboxylique comme inhibiteurs de la dgat-1
WO2013068439A1 (fr) 2011-11-09 2013-05-16 Intervet International B.V. Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
WO2013122920A1 (fr) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prévention du diabète
MX2014012465A (es) 2012-04-16 2015-01-12 Kaneq Pharma Inc Derivados de fosfonato aromaticos fusionados como precursores de inhibidores de tirosina fosfatasa de proteina 1b.
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CN108143728A (zh) 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
WO2014018350A1 (fr) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Traitement du diabète par administration d'inhibiteurs de dipeptidyl peptidase-iv
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2931734B1 (fr) 2012-12-17 2020-12-02 Merck Sharp & Dohme Corp. Nouveaux composés activateurs de glucokinase, compositions contenant de tels composés, et méthodes de traitement
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2015089809A1 (fr) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Composés hétéroaryles substitués antidiabétiques
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
WO2015176267A1 (fr) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2015189330A1 (fr) * 2014-06-12 2015-12-17 Universite De Lille 2 Droit Et Sante Dérivés d'imidazole ou de 1,2,4-triazol et leur utilisation
WO2016022742A1 (fr) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3209682B1 (fr) 2014-10-24 2020-12-30 Merck Sharp & Dohme Corp. Co-agonistes des récepteurs du glucagon et du glp-1
EA036985B1 (ru) 2014-10-31 2021-01-25 НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. Композиции и способы лечения метаболических расстройств
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
EP4445956A3 (fr) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Composé pour le traitement des affections associés à s1p1-récepteur
EP3303342B1 (fr) 2015-05-27 2021-03-17 Merck Sharp & Dohme Corp. Dérivés d'imidazo-pyrazinyle utiles à titre d'activateurs de guanylate cyclase solubles
WO2016191335A1 (fr) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Dérivés d'imidazo-pyrazinyle utiles à titre d'activateurs de guanylate cyclase solubles
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
WO2017107052A1 (fr) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Activateurs solubles de guanylate cyclase
US10000458B2 (en) * 2016-03-31 2018-06-19 Sumitomo Chemical Company, Limited Production method of 1, 2, 4-triazole compound
EP3235813A1 (fr) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Dérivés aza-tétra-cycliques
WO2017197555A1 (fr) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Dérivés de pyrazine fusionnés utiles en tant que stimulateurs de la guanylate cyclase soluble
WO2017201683A1 (fr) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Composés de tétrahydroisoquinoline substitués utiles à titre d'agonistes de gpr120
WO2018034917A1 (fr) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
EP3496716B1 (fr) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
EP3515891B1 (fr) 2016-09-20 2023-03-08 Merck Sharp & Dohme LLC Molécules de 1-méthyl -1,2,3,4-tétrahydroisoquinoléine substituées en tant que liants allostériques de pcsk9
CA3043206A1 (fr) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. Derives d'indole utiles en tant qu'inhibiteurs de la diacylglyceride o-acyltransferase 2
MA46856A (fr) 2016-11-18 2019-09-25 Merck Sharp & Dohme Dérivés d'indazole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2
WO2018107415A1 (fr) 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. Composés d'hydroxy isoxazole utiles en tant qu'agonistes de gpr120
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
WO2020167706A1 (fr) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
WO2020205688A1 (fr) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibiteurs d'histone désacétylase -3 utiles pour le traitement du cancer, de l'inflammation, de maladies neurodégénératives et du diabète
WO2021026047A1 (fr) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
US11484565B2 (en) 2019-08-30 2022-11-01 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
EP3842449A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes d'oléfine agrafés du glucagon et récepteurs glp-1
EP3842061A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes triazoles agrafés des récepteurs du glucagon et du glp-1
EP3842060A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes lactames agrafés des récepteurs du glucagon et du glp-1
TW202208359A (zh) 2020-05-18 2022-03-01 美商默沙東藥廠 新穎二醯基甘油酯o-醯基轉移酶2抑制劑
CA3189908A1 (fr) 2020-08-18 2022-02-24 Stephane L. Bogen Agonistes du recepteur de l'orexine de type bicycloheptane pyrrolidine
KR102445638B1 (ko) 2020-09-03 2022-09-20 충남대학교산학협력단 11 알파 하이드록시프로게스테론을 포함하는 당뇨병 예방 또는 치료용 조성물
MX2023003842A (es) 2020-10-08 2023-04-14 Merck Sharp & Dohme Llc Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2.
JP7482324B2 (ja) 2020-10-08 2024-05-13 メルク・シャープ・アンド・ドーム・エルエルシー 新規なジアシルグリセリドｏ－アシルトランスフェラーゼ２阻害剤としてのオキシインドール誘導体の製造
JP2024532129A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｃｓｋ９活性に関連する状態を治療するための化合物
AU2023273030A1 (en) 2022-05-16 2024-11-07 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
CN116003279B (zh) * 2022-06-13 2024-05-28 苏州大学 一种绿色的n-甲基酰胺化合物的制备方法
TW202404574A (zh) 2022-06-15 2024-02-01 美商默沙東有限責任公司 用於捕捉介白素-1 β之環狀肽
AR131250A1 (es) 2022-12-02 2025-02-26 Merck Sharp & Dohme Llc Preparación de derivados condensados de azol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
US20250152658A1 (en) 2023-11-14 2025-05-15 Merck Sharp & Dohme Llc Cyclic peptide for trapping interleukin-1 beta
WO2025128805A1 (fr) 2023-12-15 2025-06-19 Merck Sharp & Dohme Llc Piège à il-1 bêta à peptide cyclique pour le traitement de l'athérosclérose et de troubles inflammatoires
WO2026019977A1 (fr) 2024-07-19 2026-01-22 Merck Sharp & Dohme Llc Inhibiteurs de vegfr pyrrolopyridaziniques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW226993B (fr) * 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
ES2224462T3 (es) 1997-12-11 2005-03-01 Janssen Pharmaceutica N.V. Anilidas mimeticas del acido retinoico.
US20030073850A1 (en) 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
JPWO2003004497A1 (ja) 2001-07-05 2004-10-28 住友製薬株式会社 新規複素環化合物
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors

Also Published As

Publication number Publication date
US20040106664A1 (en) 2004-06-03
RU2319703C2 (ru) 2008-03-20
AU2003243420A8 (en) 2003-12-22
CN1990474A (zh) 2007-07-04
HK1081946A1 (en) 2006-05-26
AR040241A1 (es) 2005-03-23
CA2488592A1 (fr) 2003-12-18
CA2488592C (fr) 2010-08-10
WO2003104207A2 (fr) 2003-12-18
ECSP045482A (es) 2005-01-28
IS7519A (is) 2004-10-29
JO2315B1 (en) 2005-09-12
EP1532122B1 (fr) 2011-12-14
HRP20041180A2 (en) 2005-08-31
ATE537155T1 (de) 2011-12-15
JP4405384B2 (ja) 2010-01-27
MY134664A (en) 2007-12-31
NZ536188A (en) 2006-11-30
CN1312137C (zh) 2007-04-25
ES2377200T3 (es) 2012-03-23
BR0311137A (pt) 2005-02-22
IL165257A0 (en) 2005-12-18
MXPA04012381A (es) 2005-04-19
RU2004139063A (ru) 2005-06-27
PE20040726A1 (es) 2004-10-23
KR20050008805A (ko) 2005-01-21
US7179802B2 (en) 2007-02-20
AU2003251410B2 (en) 2009-05-21
UA81417C2 (en) 2008-01-10
US20040048912A1 (en) 2004-03-11
ZA200408772B (en) 2005-11-18
AU2003243420A1 (en) 2003-12-22
EP1532122A1 (fr) 2005-05-25
NO20050102L (no) 2005-02-10
CN1659151A (zh) 2005-08-24
WO2003104207A3 (fr) 2004-03-25
JP2005532357A (ja) 2005-10-27
TWI324153B (en) 2010-05-01
US6730690B2 (en) 2004-05-04
WO2003104208A1 (fr) 2003-12-18
PL373372A1 (en) 2005-08-22
TW200410947A (en) 2004-07-01
AU2003251410A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
MA27317A1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
MA27579A1 (fr) Derives de triazole comme inhibiteurs de la 11-beta-hydroxysteroide-deshydrogenase 1
MA30201B1 (fr) Derives triazoliques comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase-1
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
ATE394413T1 (de) Peptidylketone als inhibitoren der dpiv
BR0009864A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
WO2004048345A3 (fr) Composes destines au traitement de l'obesite
ATE476425T1 (de) Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
ATE329901T1 (de) 3-substituierte oxindolderivate als beta-3- agonisten
DE602005013822D1 (de) Cycloalkylaminderivate
BG106038A (en) Aminopyridines as sorbitol dehydrogenase inhibitors
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
TW200505919A (en) DPP-IV inhibitors
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
ATE471311T1 (de) Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
EA200801426A1 (ru) ПРОИЗВОДНЫЕ 2-АДАМАНТИЛМОЧЕВИНЫ В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ 11β-HSD1
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
TW200504063A (en) DPP-IV inhibitors
BR0107901A (pt) Composto, composição farmacêutica, método para o trtamento de enfermidade, para o trtamento e/ou prevenção de condições mediadas por receptores nucleares, e para o tratamento e/ou prevenção de diabetes e/ou obesidade, uso de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância à gligose prejudicada, resistência à insulina ou obesidade
BRPI0407180A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
ATE399546T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
ATE401073T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
BR0315683A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento e/ou prevenção de condições mediadas por receptores nucleares e para o tratamento e/ou prevenção do diabete do tipo i, diabete do tipo ii, tolerância à glicose prejudicada, resistência à insulina ou obesidade
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5